The FDA approved a breakthrough cancer treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma, a form of non-Hodgkin lymphoma, that uses genetically engineered immune cells to target cancer.
Lymphatic vessels, often blamed for enabling cancer cells to spread from a primary location to many other sites, have a flip side.
In a new study, UChicago researchers look to understand why some cancer tumors are more susceptible to immunotherapy than others.
Immunotherapy has revolutionized cancer treatment–but not for everyone. See how UChicago researchers are overcoming these barriers to help more patients.
University of Chicago scientists are forging unexpected collaborations in a quest to understand and harness the capability of microbes.
Many cancer patients respond favorably to immunotherapies, but most do not. Two new studies by UChicago cancer specialists in PNAS try to find out why.
Wenbin Lin and his lab are combining nanoscale metal frameworks with photosensitive molecules to deliver immunotherapy drugs to treat cancer.
Ralph Weichselbaum and his team were able to improve immunotherapy treatments for cancer by combining them with radiation and special vaccines.